profit from every $100 of sales.
$0$100
Surgery Partners
$26.95+1.39% today
+76.0% in 1 year
1-year low $11.491-year high $26.95
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Surgery Partners sold, what it kept, and what it did with the cash.
Sales went from $2.54 billion in 2022 to $3.31 billion in 2025, with -$77.9 million of profit last year.
SalesProfit
Surgery Partners vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Surgery Partners | No profit yet | ||
 Tenet Healthcare | 16.2× · Fair price | ||
 Solventum | 9.7× · Cheap | ||
 Encompass Health | 24.4× · Fair price | ||
 Fresenius Medical Care AG & Co. KGaA | 10.6× · Cheap |
AI analysis
An AI analyst reads Surgery Partners's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 2,539 | 2,743 | 3,114 | 3,309 | |
| 575 | 648 | 746 | 765 | |
| 358 | 409 | 454 | 471 | |
| 460 | 446 | 501 | 566 | |
| -55 | -12 | -168 | -78 | |
| -0.59 | -0.09 | -1.33 | -0.61 | |
| 22.6% | 23.6% | 23.9% | 23.1% | |
| 14.1% | 14.9% | 14.6% | 14.2% | |
| -2.2% | -0.4% | -5.4% | -2.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 6,682 | 6,877 | 7,890 | 8,120 |
| Cash | 283 | 196 | 270 | 240 |
| Total debt | 2,930 | 3,062 | 3,703 | 4,025 |
| Total liabilities | 3,399 | 3,515 | 4,255 | 4,593 |
| 1,998 | 1,987 | 1,790 | 1,713 | |
| 92 | 126 | 126 | 127 | |
| 5.5% | 5.1% | 5.0% | 5.4% | |
| -2.7% | -0.6% | -9.4% | -4.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 159 | 294 | 300 | 274 | |
| 81 | 89 | 90 | 79 | |
| 78 | 205 | 210 | 196 | |
| Dividends paid | 0 | 0 | – | – |
| – | – | – | – | |
| 18 | 18 | 33 | 15 |
Valuation
- –
- 71.5×
- –
- 1.1×
- 1.1×
- 18.0×
- 12.9×
- 5.5%
- -2.2%
- 0.0%
Profitability
- 23.1%
- 14.2%
- -2.4%
- 29.1%
- 4.6%
- -1.5%
- -4.4%
- -0.9%
- 5.5%
- –
Growth
- +9.2%
- –
- −6.7%
- –
- +15.1%
Financial health
- 4.0×
- 2.39
- 50.1%
- 0.6×
- 1.86
- 1.69
- 0.42
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 43%of 963
Top 39%of 894
Bottom 45%of 908
Top 20%of 991
What analysts expect
- Average price target
- $18.60
- Range
- $15.00 – $21.00
- 5 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | -0.03 | -0.15 | +80.0% |
| Mar 2, 2026 | 0.12 | 0.31 | −61.3% |
| Nov 10, 2025 | 0.13 | 0.19 | −31.6% |
| Aug 5, 2025 | 0.17 | 0.16 | +6.3% |
| May 12, 2025 | 0.04 | 0.08 | −50.0% |
| Mar 3, 2025 | 0.44 | 0.38 | +15.8% |
| Nov 12, 2024 | 0.19 | 0.25 | −24.0% |
| Aug 6, 2024 | 0.21 | 0.21 | +0.0% |
News
Bon Secours nears $6B takeover of Surgery Partners, FT reportsSeeking Alpha · Oct 25, 2026Surgery Partners (SGRY): Buy, Sell, or Hold Post Q2 Earnings?Yahoo Finance · Sep 23, 2026Plastic surgery is booming with boomers. Here’s how to cash in on the antiaging craze.MarketWatch · Sep 8, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
23No pass
Benjamin Graham
41No pass
Philip Fisher
20No pass
Peter Lynch
25No pass
Joel Greenblatt
18No pass
Charlie Munger
13No pass
Terry Smith
14No pass
Questions about Surgery Partners
Is Surgery Partners a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Surgery Partners AI analysis
What does Surgery Partners do?
Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. It is in Medical - Care Facilities.
Does Surgery Partners pay a dividend?
No. Surgery Partners does not pay a dividend at the moment.
Is Surgery Partners stock halal?
No. Surgery Partners does not pass our halal screen: its debt is 114% of its market value, at or above the 33% limit. How we check
How has Surgery Partners stock done over the past year?
Up 76.0% over the past twelve months, to $26.95. It traded between $11.49 and $26.95, close to its high.
Who are Surgery Partners's competitors?
The largest listed companies in the same industry are Tenet Healthcare, Solventum, Encompass Health and Fresenius Medical Care AG & Co. KGaA. The peers table on this page compares their profit, growth and price with Surgery Partners's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.